In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
24 authors.
Nicolas Panel *Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.ORCID 0000-0001-8782-0586 Duy Duc Vo *Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden. duc.duy.vo@kemi.uu.se.
Harald Hübner *Department of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0002-7892-599X Szymon PachScience for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.ORCID 0000-0001-6109-7123 Félix BélairDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institute de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada.
Dorothee WeikertDepartment of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0003-2259-9002 Mark HilgeDepartment of Biochemistry, University of Zurich, Zürich, Switzerland.
Niharika ShivaDepartment of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.ORCID 0009-0007-7951-4598 Isabelle BrochuDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institute de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada.
Jean-Michel LongpréDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institute de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada.ORCID 0000-0003-3985-2318 Frida BällgrenDepartment of Pharmacy, SciLifeLab Drug Discovery and Development, Uppsala University, Uppsala, Sweden.ORCID 0009-0007-4885-9120 Aljona SalehDepartment of Pharmacy, SciLifeLab Drug Discovery and Development, Uppsala University, Uppsala, Sweden.ORCID 0009-0002-2121-043X Huabin HuScience for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.
Jon KaplaScience for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.ORCID 0000-0003-3328-1921 Stefanie KampenScience for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.
Israel Cabeza de VacaScience for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-6208-1091 Nina WettschureckDepartment of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.ORCID 0000-0001-6858-1460 Philippe SarretDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institute de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada. philippe.sarret@usherbrooke.ca.ORCID 0000-0002-7627-701X Andreas PlückthunDepartment of Biochemistry, University of Zurich, Zürich, Switzerland. plueckthun@bioc.uzh.ch.ORCID 0000-0003-4191-5306 Peter GmeinerDepartment of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. peter.gmeiner@fau.de.ORCID 0000-0002-4127-197X Jens CarlssonScience for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden. jens.carlsson@icm.uu.se.ORCID 0000-0003-4623-2977 Funding
EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 715052
6 · The paper itselfAbstract
Peptide-activated G protein-coupled receptors (GPCRs) play crucial roles in numerous diseases, but remain difficult therapeutic targets due to the challenges in developing small-molecule drugs. Here, we explore structure-based strategies to identify small-molecule agonists of neurotensin (NTS) receptors, which hold promise for developing non-opioid analgesics. Chemical libraries of drug-like molecules are first designed based on a receptor-peptide complex, and then 14.5 million compounds are computationally docked to the orthosteric binding site of the NTS
Indexed as
AnalgesicsReceptors, NeurotensinSmall Molecule LibrariesAnimalsBinding SitesHumansLigandsMiceMolecular Docking SimulationProtein BindingAnalgesicsLigandsneurotensin type 1 receptorReceptors, NeurotensinSmall Molecule Libraries
Identifiers
PMID42486867
PMCPMC13392031
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390